Alamar Biosciences, a company focused on precision proteomics for early disease detection, is proud to announce the release of the NULISAqpcr™ Custom Assay Development Kit. This groundbreaking product enables scientists to develop highly sensitive and accurate biomarker assays tailored to specific research needs, expanding the application of NULISA™ technology to the broader biomarker research community.
The NULISAqpcr Custom Assay Development Kit provides unparalleled flexibility, enabling scientists to develop custom antibody-based targeted assays with exceptional sensitivity and reproducibility. The kit is ideal for areas that require high sensitivity and wide dynamic range – such as immunology, neurology and more. With its adaptability, it offers a seamless workflow from antibody conjugation to automated NULISAqpcr steps with the ARGO™ HT instrument, setting a new standard for in-house single-layer assay development.
Also Read: bluebird bio to Be Acquired by Carlyle and SK Capital
“The Custom Assay Development Kit directly addresses the growing demand from scientists looking to leverage our leading-edge NULISA technology to develop high-throughput biomarker assays for translational and clinical research,” said Yuling Luo , Ph.D., Founder, Chairman and CEO of Alamar Biosciences. “The launch represents a significant milestone in our mission to build a transformative ecosystem to support precision proteomics.”
With the launch of the NULISAqpcr Custom Assay Development Kit, Alamar continues to solidify its commitment to leading innovation and supporting the scientific community with cutting-edge solutions.
Source: PRNewswire